[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100457445":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":36,"responsibleParty":53,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":19,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":19,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":39,"whyStopped":19,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Shanghai Gynecologic Oncology Group","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hepato-celiac lymphadenectomy","EXPERIMENTAL","This single-arm, multi-center, phase II trial is to evaluate the safety and effectiveness of hepato-celiac lymphadenectomy in the treatment of ovarian cancer with hepato-celiac lymph nodes metastases, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).",[13],"Procedure: Hepato-celiac lymphadenectomy",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","Hepato-celiac lymphadenectomy in the treatment of epithelial ovarian cancer, with a maximum cytoreduction, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Rongyu Zang","Fudan University","STUDY_CHAIR",[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Libing Xiang","CONTACT","862164041990","2801","xiang.libing@zs-hospital.sh.cn",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},"Rong Jiang","86 21 64041990","jiang.rong@zs-hospital.sh.cn",[37],{"facility":38,"status":39,"city":40,"state":19,"zip":19,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Zhongshan Hospital, Fudan University","RECRUITING","Shanghai","China","CN",{"type":44,"coordinates":45},"Point",[46,47],121.45806,31.22222,{"lat":47,"lon":46},[50,51],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},{"name":27,"role":52,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[56],{"name":23,"class":57},"OTHER","100457445","survival-effect-of-hepato-celiac-lymphadenectomy-in-primary-or-relapsed-ovarian-cancer-100457445",false,"NCT05236686","Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer","A Prospective, Multi-center, Single-Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Hepato-celiac Lymphadenectomy in the Treatment of Advanced and Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* Age ≥18 years to ≤ 75 years.\n* Pathologic confirmed stage III or IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma (EOC, PPC, FTC) or platinum sensitive, relapsed EOC, PPC or FTC (no more than 4 lines of therapy)\n* Hepato-celiac lymph nodes metastases diagnosed by imaging before surgery and enlarged palpable lymph nodes by surgical findings\n* Assessed by the experienced surgeons, complete resection is feasible according to preoperative evaluation\n* 1 to 3 episodes of neoadjuvant chemotherapy is allowed in primary settings\n* Platinum sensitive relapse is defined as those with platinum-free interval of 6 months or more.\n* ASA score of 1 to 2\n* ECOG performance status of 0 to 2\n* Adequate bone marrow, liver and renal function to receive chemotherapy and subsequently to undergo surgery:\n* White blood cells \\>3,000\u002FµL, absolute neutrophil count ≥1,500\u002FµL, platelets ≥100,000\u002FµL, hemoglobin ≥9 g\u002FdL,\n* Serum creatinine \\\u003C1.25 x upper normal limit (UNL) or creatinine clearance ≥60 mL\u002Fmin according to Cockcroft-Gault formula or to local lab measurement\n* Serum bilirubin \\\u003C1.25 x UNL, AST(SGOT) and ALT(SGPT) \\\u003C2.5 x UNL\n* Comply with the study protocol and follow-up.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Patients with non-epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma.\n* Low-grade carcinoma.\n* Mucinous ovarian cancer.\n* Infeasible complete resection according to preoperative evaluation\n* Unresectable pulmonary and hepatic parenchymal metastases, multiple thoracic lymph nodes metastases, brain or bone metastases according to preoperative evaluation.\n* Carcinomatosis on small bowel mesentery or intestinal wall by surgical findings and infeasible optimal surgery by bowel resection or peritonectomy.\n* Progression after neoadjuvant chemotherapy in primary settings.\n* Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ or breast cancer (without any signs of relapse or activity).\n* Any other concurrent medical conditions contraindicating surgery or chemotherapy that could compromise the adherence to the protocol.\n* Other conditions, such as religious, psychological and other factors, that could interfere with provision of informed consent, compliance to study procedures, or follow-up.","FEMALE","18 Years","75 Years",{"count":69,"type":70},94,"ESTIMATED","INTERVENTIONAL",[73],"NA","The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian cancer and platinum-sensitive recurrent ovarian cancer.",[76,77,78],"Epithelial Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Carcinoma",[80,81,82,83],"Ovarian Cancer","Surgery","Lymph Node Metastasis","Hepato-celiac Lymphadenectomy","2025-11-16",{"date":86,"type":87},"2025-11-19","ACTUAL",{"date":89,"type":87},"2022-02-15",{"date":91,"type":70},"2025-12",{"name":5,"class":6},1]